高危肺栓塞接受VA-ECMO患者全身溶栓对临床结局的有效性:一项全国住院数据库研究
本研究为回顾性队列研究,利用日本诊断程序组合住院数据库2010年7月至2021年3月数据,纳入入院当日诊断为肺栓塞并接受VA-ECMO的患者。将启动VA-ECMO后2天内接受孟替普酶或尿激酶全身溶栓者定义为溶栓组,其余为对照组,采用倾向评分逆概率治疗加权(IPTW)比较结局。共1220例 eligible 患者,432例(35%)接受全身溶栓。IPTW后院内死亡率两组无显著差异(风险差-3.0%,95%CI -9.6%至3.5%),次要结局亦无显著差异。敏感性分析排除尿激酶后,孟替普酶组与对照组大出血风险差6.9%(95%CI 1.7%至12.1%)。结论认为全身溶栓与院内死亡率降低或大出血增加无关,但孟替普酶溶栓与大出血增加相关。
要点
- 高危肺栓塞接受VA-ECMO患者中,35%(432/1220)在启动VA-ECMO后2天内接受全身溶栓(孟替普酶或尿激酶)。
- IPTW后,溶栓组与对照组院内死亡率无显著差异(风险差-3.0%,95%CI -9.6%至3.5%)。
- 次要结局(良好神经功能、住院时长、VA-ECMO时长、总住院费用、大出血、输血量)在IPTW后均无显著差异。
- 敏感性分析排除尿激酶后,孟替普酶组大出血风险显著高于对照组(风险差6.9%,95%CI 1.7%至12.1%)。
- 除总住院费用外,其他敏感性和亚组分析均无显著差异。
适用人群与场景
- 入院当日诊断为肺栓塞并接受VA-ECMO的患者,数据来自日本诊断程序组合住院数据库2010年7月至2021年3月。
处置流程与药物剂量
- 溶栓组定义为启动VA-ECMO后2天内接受孟替普酶或尿激酶全身溶栓,对照组为其余患者。
研究设计与关键结果
- 研究类型为回顾性队列研究,使用日本诊断程序组合住院数据库2010年7月至2021年3月数据,共纳入1220例 eligible 患者,其中432例(35%)接受全身溶栓。
- 未加权队列中,溶栓组入院时意识差、院外心脏骤停和左心导管检查的比例较低;IPTW后两组特征均衡。
- 粗院内死亡率溶栓组52% vs 对照组61%;IPTW后院内死亡率无显著差异(风险差-3.0%,95%CI -9.6%至3.5%)。
- IPTW后次要结局(良好神经功能、住院时长、VA-ECMO时长、总住院费用、大出血、输血量)均无显著差异。
- 敏感性分析排除尿激酶后,孟替普酶组与对照组大出血风险差6.9%(95%CI 1.7%至12.1%)。
- 除总住院费用外,其他敏感性和亚组分析均无显著差异。
证据类型、等级与局限
- 证据类型:回顾性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,全身溶栓与接受VA-ECMO的高危肺栓塞患者院内死亡率降低或大出血增加无关;但孟替普酶全身溶栓与大出血增加相关。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Current guidelines recommend systemic thrombolysis as the first-line reperfusion treatment for patients with high-risk pulmonary embolism (PE) who present with cardiogenic shock but do not require venoarterial extracorporeal membrane oxygenation (VA-ECMO). However, little is known about the optimal reperfusion treatment in high-risk PE patients requiring VA-ECMO. We aimed to evaluate whether systemic thrombolysis improved high-risk PE patients' outcomes who received VA-ECMO.
METHODS: This was a retrospective cohort study using the Japanese Diagnosis Procedure Combination inpatient database from July 2010 to March 2021. We identified patients who were diagnosed with PE and received VA-ECMO on the day of admission. Patients who received systemic thrombolysis with monteplase or urokinase within two days of initiating VA-ECMO were defined as the thrombolysis group and the remaining patients as the control group. The primary outcome was in-hospital mortality and secondary outcomes were favorable neurological outcomes, length of hospital stay, VA-ECMO duration, total hospitalization cost, major bleeding, and blood transfusion volume. Propensity-score inverse probability of treatment weighting (IPTW) was performed to compare the outcomes between the groups.
RESULTS: Of 1220 eligible patients, 432 (35%) received systemic thrombolysis within two days of initiating VA-ECMO. Among the unweighted cohort, patients in the thrombolysis group were less likely to have poor consciousness at admission, out-of-hospital cardiac arrest, and left heart catheterization. After IPTW, the patient characteristics were well-balanced between the two groups The crude in-hospital mortality was 52% in the thrombolysis group and 61% in the control group. After IPTW, in-hospital mortality did not differ significantly between the two groups (risk difference: - 3.0%, 95% confidence interval: - 9.6% to 3.5%). There were also no significant differences in the secondary outcomes. Sensitivity analyses showed a significant difference in major bleeding between the monteplase and control groups (risk difference: 6.9%, 95% confidence interval: 1.7% to 12.1%), excluding patients who received urokinase. There were no significant differences in the other sensitivity and subgroup analyses except for the total hospitalization cost.
CONCLUSIONS: Systemic thrombolysis was not associated with reduced in-hospital mortality or increased major bleeding in the high-risk PE patients receiving VA-ECMO. However, systemic thrombolysis with monteplase was associated with increased major bleeding.
参考来源
- Nishimoto Y, Ohbe H, Matsui H, et al. Effectiveness of systemic thrombolysis on clinical outcomes in high-risk pulmonary embolism patients with venoarterial extracorporeal membrane oxygenation: a nationwide inpatient database study. J Intensive Care. 2023. PMID: 36740697. doi:10.1186/s40560-023-00651-w
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。